Netupitant/Palonosetron (Akynzeo)

A fixed combination of Netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and Palonosetron, a serotonin-3(5-HT3) receptor antagonist indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Oral Palonosetron prevents nausea vomiting during the acute phase and Netupitant prevents nausea and vomiting during both eacute in delayed phases after chemotherapy.

Administered as one capsule approximately one hour prior to the start of chemotherapy.

Can be taken with or without food.

Capsule 300 mg of Netupitant/0.5 mg of Palonosetron.

Most common adverse reactions are headache, asthenia, dyspepsia, fatigue, constipation and erythema.

Development of serotonin syndrome has been reported with 5-HT3 receptor antagonists.

Leave a Reply

Your email address will not be published. Required fields are marked *